Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caprylhydroxamic acid is a synthetic small molecule primarily used as a chelating agent and preservative in cosmetics and personal care products. It acts by binding essential transition metals such as iron and copper, which are required for the growth of microorganisms like bacteria and fungi. This chelation mechanism inhibits microbial growth in formulations[6][7][8]. In pharmaceutical contexts (notably under the synonym "capryl hydroxamic acid"), it has been described as a histone deacetylase (HDAC) inhibitor with potential anticancer activity for cutaneous T-cell lymphoma (CTCL), where it may inhibit tumor growth by blocking HDAC enzymes involved in cancer cell proliferation and survival[5]. Caprylhydroxamic acid is generally considered safe for use in cosmetics at current concentrations[2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Caprylhydroxamic acid.